The popularity of Mounjaro and Zepbound had left the company dealing with supply shortages for its active ingredient tirzepatide. The same also occurred to rival Novo Nordisk, which has seen supply shortages for semaglutide, the active ingredient in its GLP-1 drugs Ozempic and Wegovy.